Like most blue-chip biotech stocks and Big Pharma companies, Celgene (NASDAQ:CELG) has had a rocky year, vacillating between being up and down multiple times. Yet despite the turbulence, and being down 1% year-to-date through Dec. 14, 2015, Celgene’s turned in some pretty substantial growth.
For instance, multiple myeloma drug Revlimid just keeps tearing higher.
